Research programme: multiple sclerosis therapeutics - Evotec AG

Drug Profile

Research programme: multiple sclerosis therapeutics - Evotec AG

Latest Information Update: 26 Sep 2014

Price : $50

At a glance

  • Originator Evotec AG
  • Developer Deutsches Rheuma-Forschungszentrum; Evotec AG; University Medical Center Hamburg-Eppendorf
  • Class
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Multiple sclerosis

Most Recent Events

  • 24 Sep 2014 Early research in Multiple sclerosis in Germany (unspecified route)
  • 24 Sep 2014 Evotec collaborates with the Deutsches Rheuma-Forschungszentrum and University Medical Center, Hamburg-Eppendorf, for three research projects supported by research funds from the German Federal Ministry of Education and Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top